RELATIONSHIP OF A DOMINANT ADVANCED GLYCATION END PRODUCT, SERUM CARBOXYMETHYL-LYSINE, AND ABNORMAL GLUCOSE METABOLISM IN ADULTS: THE BALTIMORE LONGITUDINAL STUDY OF AGING

Background and Objectives: Although hyperglycemia is thought to increase the generation of advanced glycation end products (AGEs), studies have not shown a consistent relationship between abnormal glucose metabolism and serum AGEs. We investigated the relationship between a dominant serum AGE, Ncarboxymethyl- lysine (CML), and glucose metabolism. Subjects and Methods: Serum CML, fasting plasma glucose, and glucose tolerance were measured in 755 adults in the Baltimore Longitudinal Study of Aging. Fasting plasma glucose was categorized as normal (≤99 mg/dL), impaired (100-125 mg/dL), and diabetic (>125 mg/dL). Two-hour plasma glucose on oral glucose tolerance testing was categorized as normal (≤139 mg/dL), impaired (140-199 mg/dL), and diabetic (≥200 mg/dL). Results: The proportion of adults with normal, impaired, and diabetic fasting plasma glucose was 73.8%, 22.9%, and 2.9%, respectively, and the proportion with normal, impaired, and diabetic 2-hour plasma glucose was 73.1%, 19.2%, and 7.7%, respectively. Serum CML ( g/mL) was not associated with abnormal fasting plasma glucose (Odds Ratio [O.R.] 0.60, 95% Confidence Interval [C.I.] 0.15-2.36, P = 0.47) in a multivariate, ordered logistic regression model, adjusting for age, race, gender, body mass index, and chronic diseases. Serum CML ( g/mL) was associated with abnormal 2-hour plasma glucose on glucose tolerance testing (O.R. 0.15, 95% C.I. 0.04-0.63, P = 0.009) in a multivariate, ordered logistic regression model, adjusting for the same covariates. Conclusions: Elevated CML, a dominant AGE, was not associated with elevated fasting plasma glucose and was associated with a reduced odds of abnormal glucose tolerance in older community-dwelling adults